These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 15954440)

  • 21. Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig.
    Knoerzer DB; Karr RW; Schwartz BD; Mengle-Gaw LJ
    J Clin Invest; 1995 Aug; 96(2):987-93. PubMed ID: 7543497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL.
    Lanier LL; O'Fallon S; Somoza C; Phillips JH; Linsley PS; Okumura K; Ito D; Azuma M
    J Immunol; 1995 Jan; 154(1):97-105. PubMed ID: 7527824
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of human peripheral blood dendritic cells induces the CD86 co-stimulatory molecule.
    McLellan AD; Starling GC; Williams LA; Hock BD; Hart DN
    Eur J Immunol; 1995 Jul; 25(7):2064-8. PubMed ID: 7542604
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential effects of CTLA-4 substitutions on the binding of human CD80 (B7-1) and CD86 (B7-2).
    Morton PA; Fu XT; Stewart JA; Giacoletto KS; White SL; Leysath CE; Evans RJ; Shieh JJ; Karr RW
    J Immunol; 1996 Feb; 156(3):1047-54. PubMed ID: 8557978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Strength of TCR signal determines the costimulatory requirements for Th1 and Th2 CD4+ T cell differentiation.
    Tao X; Constant S; Jorritsma P; Bottomly K
    J Immunol; 1997 Dec; 159(12):5956-63. PubMed ID: 9550393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Co-stimulatory modulation in rheumatoid arthritis: the role of (CTLA4-Ig) abatacept.
    Fiocco U; Sfriso P; Oliviero F; Pagnin E; Scagliori E; Campana C; Dainese S; Cozzi L; Punzi L
    Autoimmun Rev; 2008 Oct; 8(1):76-82. PubMed ID: 18718877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of human T cell proliferation by CTLA-4 utilizes CD80 and requires CD25+ regulatory T cells.
    Manzotti CN; Tipping H; Perry LC; Mead KI; Blair PJ; Zheng Y; Sansom DM
    Eur J Immunol; 2002 Oct; 32(10):2888-96. PubMed ID: 12355442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The inhibitor of costimulation of T cells: abatacept.
    Iannone F; Lapadula G
    J Rheumatol Suppl; 2012 Jul; 89():100-2. PubMed ID: 22751606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Costimulation blockade in autoimmunity and transplantation.
    Vincenti F
    J Allergy Clin Immunol; 2008 Feb; 121(2):299-306; quiz 307-8. PubMed ID: 18269922
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Belatacept, a new original molecule, immunosuppressive, in organ transplantation].
    Beaudreuil S; Durrbach A; Kriaa F; Charpentier B
    Med Sci (Paris); 2006 Apr; 22(4):354-5. PubMed ID: 16597399
    [No Abstract]   [Full Text] [Related]  

  • 31. CD28 and CTLA4 coordinately regulate airway inflammatory cell recruitment and T-helper cell differentiation after inhaled allergen.
    Burr JS; Kimzey SL; Randolph DR; Green JM
    Am J Respir Cell Mol Biol; 2001 May; 24(5):563-8. PubMed ID: 11350825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulation of cell cycle progression by CTLA4-CD80/CD86 interactions on CD4+ T cells depends on strength of the CD3 signal: critical role for IL-2.
    Mukherjee S; Ahmed A; Malu S; Nandi D
    J Leukoc Biol; 2006 Jul; 80(1):66-74. PubMed ID: 16624934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synovial fluid transforming growth factor beta inhibits dendritic cell-T lymphocyte interactions in patients with chronic arthritis.
    Summers KL; O'Donnell JL; Heiser A; Highton J; Hart DN
    Arthritis Rheum; 1999 Mar; 42(3):507-18. PubMed ID: 10088774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression and contribution of B7-1 (CD80) and B7-2 (CD86) in the early immune response to Leishmania major infection.
    Elloso MM; Scott P
    J Immunol; 1999 Jun; 162(11):6708-15. PubMed ID: 10352289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The B7/CD28/CTLA4 T-cell activation pathway. Implications for inflammatory lung disease.
    Green JM
    Am J Respir Cell Mol Biol; 2000 Mar; 22(3):261-4. PubMed ID: 10696061
    [No Abstract]   [Full Text] [Related]  

  • 36. The B7-CD28 superfamily.
    Sharpe AH; Freeman GJ
    Nat Rev Immunol; 2002 Feb; 2(2):116-26. PubMed ID: 11910893
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunosuppressive effect of ASP2408, a novel CD86-selective variant of CTLA4-Ig, in rats and cynomolgus monkeys.
    Oshima S; Fujii Y; Karrer EE; Takamura F; Chapin SJ; Neighbors M; Viswanathan S; Devens BH; Higashi Y; Mizuhara H
    Int Immunopharmacol; 2016 Nov; 40():310-317. PubMed ID: 27662596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [CTLA4-Ig (abatacept)].
    Harigai M
    Nihon Rinsho; 2007 Jul; 65(7):1231-7. PubMed ID: 17642237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis.
    Hombach A; Sent D; Schneider C; Heuser C; Koch D; Pohl C; Seliger B; Abken H
    Cancer Res; 2001 Mar; 61(5):1976-82. PubMed ID: 11280755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pharmacological properties and clinical efficacy of abatacept (Orencia(®)) for the treatment of rheumatoid arthritis].
    Yasuoka Y; Goto A; Seriu T
    Nihon Yakurigaku Zasshi; 2011 Feb; 137(2):87-94. PubMed ID: 21321458
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.